Ketamine stock prices rise for medical use companies in 2027

The sentencing may accelerate FDA approval timelines or investment in ketamine-based therapies due to increased media attention on its medical applications. Companies like Johnson & Johnson or smaller biotechs developing ketamine treatments could see stock gains.

Implied probability (Yes)

55%

Closes

2027-12-31